Dr. Göran Ando
Vice-Chairman of the Board of Directors
Dr. Göran Ando is the Vice-Chairman of Molecular Partners. He is the retired Chairman of the board of directors of Novo Nordisk A/S. He was CEO of Celltech Group plc, UK, until 2004. Dr. Ando joined Celltech from Pharmacia, now Pfizer, US, where he was Executive Vice President (EVP) and President of Research and Development (R&D) with additional responsibilities in manufacturing, information technology, business development and Mergers & Acquisitions (M&A) (1995-2003). He was Medical Director, moving to deputy R&D Director and then R&D Director of Glaxo Group, UK (1989-1995). Dr. Ando was also a member of the Glaxo Group Executive Committee. He is a specialist in general medicine and a founding fellow of the American College of Rheumatology in the U.S. Dr. Ando serves as Chairman of the board of directors of Symphogen A/S, Denmark, and is a member of the board of directors of EUSA Pharma, UK, ICMEC, U.S. and PAREXEL, U.S. and Tessa Therapeutics, Singapore. Dr. Ando also serves as a Senior Advisor to EW Healthcare Partners and Advisor to the Board of EDBI, Singapore. Dr. Ando has been a member of the board of directors of Novo Holdings A/S, Denmark, from which he stepped down as of March 15, 2018. Dr. Ando qualified as a medical doctor at Linköping Medical University, Sweden, in 1973 and as a specialist in general medicine in 1978.